Details for New Drug Application (NDA): 065013
✉ Email this page to a colleague
NDA 065013 describes TOBRAMYCIN SULFATE, which is a drug marketed by Apothecon, Baxter Hlthcare Corp, Epic Pharma Llc, Eugia Pharma, Fresenius Kabi Usa, Gland Pharma Ltd, Hikma, Hospira, Igi Labs Inc, Mylan Labs Ltd, Slate Run Pharma, Teva Pharms Usa, Watson Labs Inc, Xellia Pharms Aps, and Xgen Pharms, and is included in thirty-two NDAs. It is available from eleven suppliers. Additional details are available on the TOBRAMYCIN SULFATE profile page.
The generic ingredient in TOBRAMYCIN SULFATE is tobramycin sulfate. There are eighteen drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the tobramycin sulfate profile page.
The generic ingredient in TOBRAMYCIN SULFATE is tobramycin sulfate. There are eighteen drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the tobramycin sulfate profile page.
Summary for 065013
| Tradename: | TOBRAMYCIN SULFATE |
| Applicant: | Xgen Pharms |
| Ingredient: | tobramycin sulfate |
| Patents: | 0 |
Suppliers and Packaging for NDA: 065013
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| TOBRAMYCIN SULFATE | tobramycin sulfate | INJECTABLE;INJECTION | 065013 | ANDA | XGen Pharmaceuticals DJB, Inc. | 39822-0412 | 39822-0412-1 | 1 VIAL in 1 CARTON (39822-0412-1) / 30 mL in 1 VIAL |
| TOBRAMYCIN SULFATE | tobramycin sulfate | INJECTABLE;INJECTION | 065013 | ANDA | XGen Pharmaceuticals DJB, Inc. | 39822-0412 | 39822-0412-6 | 6 VIAL in 1 CARTON (39822-0412-6) / 30 mL in 1 VIAL |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | EQ 1.2GM BASE/VIAL | ||||
| Approval Date: | Aug 17, 2001 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
